Kyverna Therapeutics, Inc. PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Kyverna Therapeutics, Inc. pe ratio for the quarter ending 2026-06-30 was -3.6, a change of -2.76 year-over-year.
- Kyverna Therapeutics, Inc. pe ratio for the quarter ending 2026-03-31 was -3.35, a change of -2.77 year-over-year.
- Kyverna Therapeutics, Inc. pe ratio for the quarter ending 2025-12-31 was -3.51, a change of -2.24 year-over-year.
- Kyverna Therapeutics, Inc. pe ratio for the quarter ending 2025-09-30 was -1.63, a change of 0.28 year-over-year.
- Kyverna Therapeutics, Inc. pe ratio for fiscal 2026 was -3.6.
- Kyverna Therapeutics, Inc. pe ratio for fiscal 2025 was -3.51, a change of -2.24 from fiscal 2024.
- Kyverna Therapeutics, Inc. pe ratio for fiscal 2024 was -1.27.
- Available history
- 2024-03-31 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |